Is Waldencast plc (WALD) a Buy, Sell, or Hold?
NASDAQ : WALD
Waldencast plc
$1.73 USD
$0.02 (1.17%)
- Volume
- 778.06K
- Average Volume
- 665.09K
- Market Capitalization
- $204.56M
- P/E Ratio
- -0.86
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.22
- Year Low
- $0.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.70
Company Overview
NASDAQ
Michel Brousset
Household & Personal Products
Consumer Defensive
WALD
367
GB
USD
Liquidity Metrics
0.32
1.70
0.97
0.43
0.00
Sales & Valuation
$272.07M
0.75
0.44
-12.59
-0.14
Profitability
-$2.01
-$229.75M
-84.44%
-96.39%
-47.81%
-28.15%
P/E Metrics
-0.86
-0.01
-0.01
Analyst Price Target & Rating
$3.00
$3.00
$3.00
2/5
4 Analysts
-42.33%
Financial Health Scores
-0.85
4/9
$52.4M
$816.2M
$316.1M
-$265.37M
Key Metrics (TTM)
$321.67M
1.18
-2.11
1.70
-47.81%
-7.84%
-112.34%
-7.94%
126 days
Company Executives
| Name | Title |
|---|---|
| Michel Brousset | Founder, Chief Executive Officer & Director |
| Elisabeth Milan | General Counsel |
| Hind Sebti | Co-Founder, Chief Growth Officer & Director |
| Manuel Manfredi | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Waldencast plc (NASDAQ:WALD) Stock
Waldencast Plc develops and operates a beauty and wellness platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It intends to seek brands with a direct connection to consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. The company was founded by Michel Brousset and Hind Sebti on December 8, 2020 and is headquartered in White Plains, NY. ...
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
2026-07-30 16:30:00
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
2026-06-15 09:00:00
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (“HA”) gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand. This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive leader at the intersection of advanced skincare and medical aesthetics.
Waldencast Announces Sale of Obagi Medical to Bridgepoint
2026-06-01 06:59:00
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
2026-05-15 08:13:00
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
2026-05-14 08:15:00
A multi-city pop-up introducing consumers to the future of skincare and longevity innovation A multi-city pop-up introducing consumers to the future of skincare and longevity innovation
Frequently Asked Questions
-
What is the current Waldencast plc (WALD) stock price?
-
Waldencast plc(NASDAQ:WALD) stock price is $1.73 in the last trading session. During the trading session, WALD stock reached the peak price of $3.22 while $0.72 was the lowest point it dropped to. The percentage change in WALD stock occurred in the recent session was 1.17% while the dollar amount for the price change in WALD stock was $0.02.
-
WALD's industry and sector of operation?
-
The NASDAQ listed WALD is part of Household & Personal Products industry that operates in the broader Consumer Defensive sector.
-
Who are the executives of WALD?
-
Michel Brousset | Founder, Chief Executive Officer & Director
Elisabeth Milan | General Counsel
Hind Sebti | Co-Founder, Chief Growth Officer & Director
Manuel Manfredi | Chief Financial Officer
| -
How many employees does WALD have?
-
Number of WALD employees currently stands at 367. WALD operates from 81 Fulham Road, London, SW3 6RD, GB.
-
Link for WALD official website?
-
Official Website of WALD is: http://www.waldencast.com
-
How do I contact WALD?
-
WALD could be contacted at phone #917 546 6828 and can also be accessed through its website. WALD operates from 81 Fulham Road, London, SW3 6RD, GB.
-
How many shares of WALD are traded daily?
-
The average number of WALD shares traded daily for last 3 months was 665.09K.
-
What is the market cap of WALD currently?
-
The market value of WALD currently stands at $204.56M with its latest stock price at $1.73